Co-delivery of a hydrophobic small molecule and a hydrophilic peptide by porous silicon nanoparticles.
暂无分享,去创建一个
Vesa-Pekka Lehto | Jarno Salonen | Hélder A Santos | Jouni Hirvonen | Dongfei Liu | Ermei Mäkilä | Martti Kaasalainen | Karl-Heinz Herzig | H. Santos | C. Caramella | K. Herzig | J. Salonen | V. Lehto | E. Mäkilä | B. Herranz-Blanco | J. Hirvonen | L. M. Bimbo | Barbara Herranz-Blanco | Carla M Caramella | Dongfei Liu | F. Villanova | Martti Kaasalainen | Luis M Bimbo | Francesca Villanova | B. Herranz‐Blanco
[1] Clemens Burda,et al. Nanoparticle mediated non-covalent drug delivery. , 2013, Advanced drug delivery reviews.
[2] Jarno Salonen,et al. Nanostructured Porous Silicon‐Solid Lipid Nanocomposite: Towards Enhanced Cytocompatibility and Stability, Reduced Cellular Association, and Prolonged Drug Release , 2013 .
[3] K. Järvinen,et al. Development of porous silicon nanocarriers for parenteral peptide delivery. , 2013, Molecular pharmaceutics.
[4] Anne L. van de Ven,et al. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. , 2013, Nature nanotechnology.
[5] F. Kratz,et al. Finding the optimal balance: challenges of improving conventional cancer chemotherapy using suitable combinations with nano-sized drug delivery systems. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[6] Biana Godin,et al. Biocompatibility assessment of Si-based nano- and micro-particles. , 2012, Advanced drug delivery reviews.
[7] H. Santos,et al. Nanostructured porous silicon materials: potential candidates for improving drug delivery. , 2012, Nanomedicine.
[8] Vesa-Pekka Lehto,et al. Effect of isotonic solutions and peptide adsorption on zeta potential of porous silicon nanoparticle drug delivery formulations. , 2012, International journal of pharmaceutics.
[9] H. Santos,et al. Cellular interactions of surface modified nanoporous silicon particles. , 2012, Nanoscale.
[10] Bruno Sarmento,et al. Cell-based in vitro models for predicting drug permeability , 2012, Expert opinion on drug metabolism & toxicology.
[11] H. Santos,et al. The mucoadhesive and gastroretentive properties of hydrophobin-coated porous silicon nanoparticle oral drug delivery systems. , 2012, Biomaterials.
[12] S. Sahoo,et al. Folate Decorated Dual Drug Loaded Nanoparticle: Role of Curcumin in Enhancing Therapeutic Potential of Nutlin-3a by Reversing Multidrug Resistance , 2012, PloS one.
[13] H. Gu,et al. Delivering hydrophilic and hydrophobic chemotherapeutics simultaneously by magnetic mesoporous silica nanoparticles to inhibit cancer cells , 2012, International journal of nanomedicine.
[14] H. Santos,et al. Intravenous delivery of hydrophobin-functionalized porous silicon nanoparticles: stability, plasma protein adsorption and biodistribution. , 2012, Molecular pharmaceutics.
[15] Mauro Ferrari,et al. Mesoporous Silicon‐PLGA Composite Microspheres for the Double Controlled Release of Biomolecules for Orthopedic Tissue Engineering , 2012 .
[16] Mesoporous Silicon (PSi) for Sustained Peptide Delivery: Effect of PSi Microparticle Surface Chemistry on Peptide YY3-36 Release , 2012, Pharmaceutical Research.
[17] H. Santos,et al. Functional hydrophobin-coating of thermally hydrocarbonized porous silicon microparticles. , 2011, Biomaterials.
[18] M. Brandl,et al. Effect of the non-ionic surfactant Poloxamer 188 on passive permeability of poorly soluble drugs across Caco-2 cell monolayers. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[19] H. Santos,et al. ¹⁸F-labeled modified porous silicon particles for investigation of drug delivery carrier distribution in vivo with positron emission tomography. , 2011, Molecular Pharmaceutics.
[20] H. Santos,et al. Multifunctional porous silicon for therapeutic drug delivery and imaging. , 2011, Current drug discovery technologies.
[21] Liangfang Zhang,et al. Polymeric nanoparticles with precise ratiometric control over drug loading for combination therapy. , 2011, Molecular pharmaceutics.
[22] V. Rotello,et al. Beauty is skin deep: a surface monolayer perspective on nanoparticle interactions with cells and bio-macromolecules. , 2011, Small.
[23] B. Sarmento,et al. Facilitated nanoscale delivery of insulin across intestinal membrane models. , 2011, International journal of pharmaceutics.
[24] H. Santos,et al. Drug permeation across intestinal epithelial cells using porous silicon nanoparticles. , 2011, Biomaterials.
[25] Guojie Wang,et al. Drug delivery systems for differential release in combination therapy , 2011, Expert opinion on drug delivery.
[26] S. Yadav,et al. Cellular interactions of therapeutically delivered nanoparticles , 2011, Expert opinion on drug delivery.
[27] K. Järvinen,et al. Nanostructured porous silicon microparticles enable sustained peptide (Melanotan II) delivery. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[28] Robert Langer,et al. Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy , 2010, Proceedings of the National Academy of Sciences.
[29] W. Freeman,et al. Sustained Release of a Monoclonal Antibody from Electrochemically Prepared Mesoporous Silicon Oxide , 2010, Advanced functional materials.
[30] C. Prestidge,et al. Thermal oxidation for controlling protein interactions with porous silicon. , 2010, Langmuir : the ACS journal of surfaces and colloids.
[31] Liangfang Zhang,et al. Nanoparticle-assisted combination therapies for effective cancer treatment. , 2010, Therapeutic delivery.
[32] Zongxi Li,et al. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. , 2010, ACS nano.
[33] Liangfang Zhang,et al. Combinatorial drug conjugation enables nanoparticle dual-drug delivery. , 2010, Small.
[34] H. Santos,et al. In vitro cytotoxicity of porous silicon microparticles: effect of the particle concentration, surface chemistry and size. , 2010, Acta biomaterialia.
[35] Vesa-Pekka Lehto,et al. Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats. , 2010, ACS nano.
[36] Mauro Ferrari,et al. Sustained small interfering RNA delivery by mesoporous silicon particles. , 2010, Cancer research.
[37] He Hui,et al. Oxidized mesoporous silicon microparticles for improved oral delivery of poorly soluble drugs. , 2010, Molecular pharmaceutics.
[38] Francesco Stellacci,et al. Effect of surface properties on nanoparticle-cell interactions. , 2010, Small.
[39] M. Wirth,et al. Poloxamer 188 supplemented culture medium increases the vitality of Caco-2 cells after subcultivation and freeze/thaw cycles. , 2010, ALTEX.
[40] Iseult Lynch,et al. Protein-nanoparticle interactions: What does the cell see? , 2009, Nature nanotechnology.
[41] Vesa-Pekka Lehto,et al. In vivo delivery of a peptide, ghrelin antagonist, with mesoporous silicon microparticles. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[42] T. Xia,et al. Understanding biophysicochemical interactions at the nano-bio interface. , 2009, Nature materials.
[43] Lasse Murtomäki,et al. Cellular automata model for drug release from binary matrix and reservoir polymeric devices. , 2009, Biomaterials.
[44] Michael J Sailor,et al. Biodegradable luminescent porous silicon nanoparticles for in vivo applications. , 2009, Nature materials.
[45] W. Freeman,et al. Porous silicon in drug delivery devices and materials. , 2008, Advanced drug delivery reviews.
[46] M. Morris,et al. Delivery of proteins and nucleic acids using a non-covalent peptide-based strategy. , 2008, Advanced drug delivery reviews.
[47] Mauro Ferrari,et al. Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. , 2008, Nature nanotechnology.
[48] M. Sailor,et al. Digital microfluidics and delivery of molecular payloads with magnetic porous silicon chaperones. , 2008, Dalton transactions.
[49] Omid C Farokhzad,et al. Co‐Delivery of Hydrophobic and Hydrophilic Drugs from Nanoparticle–Aptamer Bioconjugates , 2007, ChemMedChem.
[50] U. Schaefer,et al. Dexamethasone-loaded nanoparticle-coated microparticles: correlation between in vitro drug release and drug transport across Caco-2 cell monolayers. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[51] A. Almeida,et al. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. , 2007, Advanced drug delivery reviews.
[52] J. Salonen,et al. Enhanced in vitro permeation of furosemide loaded into thermally carbonized mesoporous silicon (TCPSi) microparticles. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[53] Ho Sup Yoon,et al. Co-delivery of drugs and DNA from cationic core–shell nanoparticles self-assembled from a biodegradable copolymer , 2006, Nature materials.
[54] Y. Kawashima,et al. Biodegradable nanoparticles loaded with insulin-phospholipid complex for oral delivery: preparation, in vitro characterization and in vivo evaluation. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[55] V. Lehto,et al. Mesoporous silicon microparticles for oral drug delivery: loading and release of five model drugs. , 2005, Journal of controlled release : official journal of the Controlled Release Society.
[56] H. Gao,et al. Synthesis of a biodegradable tadpole-shaped polymer via the coupling reaction of polylactide onto mono(6-(2-aminoethyl)amino-6-deoxy)-beta-cyclodextrin and its properties as the new carrier of protein delivery system. , 2005, Journal of controlled release : official journal of the Controlled Release Society.
[57] N. C. Price,et al. How to study proteins by circular dichroism. , 2005, Biochimica et biophysica acta.
[58] Shiladitya Sengupta,et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system , 2005, Nature.
[59] V. Rives,et al. Mg,Al layered double hydroxides with intercalated indomethacin: synthesis, characterization, and pharmacological study. , 2004, Journal of pharmaceutical sciences.
[60] P. Mannon,et al. Primary structures of PYY, [Pro(34)]PYY, and PYY-(3-36) confer different conformations and receptor selectivity. , 2000, American journal of physiology. Gastrointestinal and liver physiology.
[61] P Couvreur,et al. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. , 2000, Biomaterials.
[62] G L Amidon,et al. Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport. , 2000, Journal of pharmaceutical sciences.
[63] A. Price,et al. Mitochondrial damage: a possible mechanism of the “topical” phase of NSAID induced injury to the rat intestine , 1997, Gut.
[64] K. Luthman,et al. Caco-2 monolayers in experimental and theoretical predictions of drug transport , 1996 .
[65] G. Amidon,et al. HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: in vitro-in vivo correlation with permeability data from rats and humans. , 1996, Journal of pharmaceutical sciences.
[66] R. Conradi,et al. The relationship between peptide structure and transport across epithelial cell monolayers , 1992 .
[67] E. Teller,et al. ADSORPTION OF GASES IN MULTIMOLECULAR LAYERS , 1938 .